Logo

WGSWW

GeneDx Holdings Corp.

WGSWW

GeneDx Holdings Corp. • NASDAQ
$0.06 ▲ 9.80% (+0.01)
Market Cap $1.62 M
52w High $0.08
52w Low $0.05
Dividend Yield 0%
P/E 0
Volume 57.93K
Outstanding Shares 28.91M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $116.743M ▲ $87.778M ▲ $-7.635M ▼ -6.54% ▼ $-0.27 ▼ $-352K ▼
Q2-2025 $102.692M ▲ $61.942M ▼ $10.809M ▲ 10.526% ▲ $0.38 ▲ $17.571M ▲
Q1-2025 $87.115M ▼ $63.027M ▲ $-6.529M ▼ -7.495% ▼ $-0.23 ▼ $236K ▼
Q4-2024 $95.64M ▲ $57.399M ▲ $5.438M ▲ 5.686% ▲ $0.2 ▲ $14.364M ▲
Q3-2024 $76.874M $55.609M $-8.312M -10.812% $-0.31 $-1.851M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $155.079M ▲ $493.902M ▲ $201.644M ▲ $292.258M ▲
Q2-2025 $134.558M ▼ $463.863M ▲ $186.73M ▼ $277.133M ▲
Q1-2025 $159.16M ▲ $446.43M ▲ $189.025M ▲ $257.405M ▲
Q4-2024 $141.185M ▲ $419.38M ▲ $174.133M ▼ $245.247M ▲
Q3-2024 $116.46M $408.84M $204.339M $204.501M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-7.635M ▼ $15.767M ▲ $-4.687M ▲ $10.768M ▲ $21.848M ▲ $9.595M ▲
Q2-2025 $10.809M ▲ $10.42M ▲ $-36.35M ▼ $346K ▼ $-25.584M ▼ $8.051M ▲
Q1-2025 $-6.529M ▼ $10.182M ▲ $-9.408M ▼ $13.718M ▼ $14.492M ▼ $4.053M ▲
Q4-2024 $5.438M ▲ $-3.183M ▲ $-519K ▲ $31.023M ▲ $27.321M ▲ $-6.233M ▼
Q3-2024 $-8.312M $-4.395M $-7.755M $13.968M $1.818M $-5.041M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Diagnostic Test
Diagnostic Test
 $160.00M ▲$90.00M ▼$100.00M ▲$110.00M ▲
Diagnostic Test Institutional Customers
Diagnostic Test Institutional Customers
 $30.00M ▲$20.00M ▼$20.00M ▲$20.00M ▲
Diagnostic Test Self Pay
Diagnostic Test Self Pay
 $0 ▲$0 ▲$0 ▲$0 ▲
Diagnostic Test Third Party Insurance
Diagnostic Test Third Party Insurance
 $120.00M ▲$70.00M ▼$80.00M ▲$100.00M ▲
Product and Service Other
Product and Service Other
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has been climbing over the five‑year period, with a soft patch in the middle but clear growth more recently. The company has moved from roughly break-even or slightly negative gross profit to generating a much healthier gross margin, which suggests better pricing, mix, or cost control in delivering tests and services. Despite that progress, the business is still loss-making. Operating losses and EBITDA losses were quite heavy a few years ago but have narrowed meaningfully, indicating that scale, restructuring, or cost discipline are starting to show up in the numbers. Net losses have followed the same pattern: still present, but far smaller than at the low point. Per‑share losses remain large, which reflects both the early‑stage profile of the business and past dilution. Overall, the income statement tells a story of a company moving from deep, early-stage losses toward a more sustainable model, but not yet at profitability and still dependent on continued execution to close that gap.

Balance Sheet

Balance Sheet The balance sheet has improved compared with five years ago. The company has grown its asset base and, importantly, repaired shareholders’ equity from negative territory to positive levels. That signals that prior balance sheet stress has been addressed through capital raises, restructuring, or both. Cash balances, while not large, are relatively stable in recent years after a spike during the SPAC period. This suggests some cushion, but not an abundance of dry powder given the ongoing cash burn. Debt is present but modest relative to total assets and equity, so financial leverage does not appear excessive at this stage. In short, the balance sheet looks cleaner and more stable than in the past, but the company is not sitting on excess liquidity, and its health still depends on reducing losses or accessing capital when needed.

Cash Flow

Cash Flow The company has consistently used cash rather than generated it. Operating cash flow has been negative every year, with the heaviest outflows in the middle of the period and a noticeable improvement more recently. This pattern matches the move from very large accounting losses toward smaller ones. Free cash flow is also negative, but capital spending is quite light. Most of the cash burn is coming from operating activities, not big investments in physical assets. That means the key lever for turning cash flow positive is further scaling revenue and tightening operating costs, rather than cutting capital expenditures. The trend is encouraging—cash burn has been shrinking—but the business is still not self-funding. Its trajectory is moving in the right direction, yet the need for external funding remains a central risk until operating cash flow turns positive and stays there.

Competitive Edge

Competitive Edge GeneDx operates in a specialized niche within healthcare information services, focused on genomic testing and interpretation, especially for rare diseases and pediatric care. Its core advantage is a very large and curated rare-disease dataset, built over many years, which makes its interpretations more accurate and reliable. This data scale is hard and time‑consuming for rivals to replicate. On top of the data, GeneDx has an AI‑driven interpretation platform that helps clinicians move from raw sequencing to clear clinical answers. The acquisition of Fabric Genomics strengthened this position and enabled a flexible model: GeneDx can run tests in its own labs or let hospitals do the sequencing and use its software for interpretation. That combination of services plus software creates switching costs and deeper integration with health systems. The company is also an early leader in areas like ultra‑rapid genome sequencing in intensive care units and genomic newborn screening, which could become large, standards‑driven markets if payers and regulators support them. At the same time, GeneDx faces intense competition from other genomic and diagnostic companies, relies on reimbursement and regulatory decisions, and must keep up with rapid technological change. Its moat is meaningful but not unassailable, and continued investment and execution are crucial.

Innovation and R&D

Innovation and R&D Innovation is the core of GeneDx’s strategy. The company invests heavily in AI and data science to interpret genomes faster and more accurately, using its Centrellis and Fabric Genomics platforms to turn complex data into practical guidance for doctors. It is pushing the frontier in several directions: ultra‑rapid sequencing for critically ill newborns, large-scale genomic newborn screening programs, and expanding use of its interpretation tools as a cloud‑based service for hospitals around the world. Participation in major research initiatives and NIH‑funded studies strengthens its scientific credibility and may help drive future clinical adoption. GeneDx is also building bridges to the pharmaceutical industry, offering de‑identified genomic data and analytics that can support drug discovery, target identification, and clinical trial enrollment. New work on broader risk tools, such as polygenic risk scores for common diseases, shows an ambition to move beyond rare disorders over time. Overall, the company is highly innovation‑driven, with R&D aimed at both improving clinical care and creating new data‑ and software‑based revenue streams, but these initiatives will take time to fully translate into stable, large-scale commercial returns.

Summary

GeneDx today looks like an advanced, innovation‑heavy healthcare data company that is still in the transition from a research‑centric profile to a more mature commercial business. Financially, revenue and gross margins are improving and losses are narrowing, but the company remains unprofitable and continues to burn cash. The balance sheet has been repaired from earlier stress, with positive equity and manageable debt, yet the cash cushion is not large relative to ongoing outflows. Continued access to capital and further progress toward break‑even are key uncertainties. Strategically, GeneDx’s strengths lie in its rare‑disease dataset, AI‑powered interpretation platform, and early leadership in genomic newborn screening and rapid sequencing in critical care. Its flexible model—offering both testing services and software—gives it multiple paths to growth and deeper integration with health systems and pharmaceutical partners. Looking ahead, the company’s prospects hinge on converting its scientific and data advantages into durable, reimbursed, and scalable revenue streams faster than its cash is consumed, while navigating competition, regulation, and reimbursement dynamics in a rapidly evolving genomics landscape.